Health · Pharma & Biotech · 12 hrs ago
South Korea approved 203 biopharmaceutical trials through September
South Korea approved 203 biopharmaceutical trials from January through September 2026.
Approvals rose each quarter, from 53 in the first quarter to 61 in the second and 89 in the third.
In the third quarter, 78 of the 89 trials involved multiple countries, while 11 were conducted in one country.
More than half of third-quarter approvals were for late-stage Phase 3 trials, which test treatments in larger groups of people.
Antibody medicines made up nearly three-quarters of the quarter’s trials, and cancer studies were the largest treatment area.
The figures cover approved trials in South Korea, but exclude studies where a biopharmaceutical was only a control or supporting treatment, as well as researcher-led and extension trials.
The association began publishing these quarterly figures this year, and the available figures go through September.
South Korea approved 203 biopharmaceutical clinical trials from January through September 2026.
Approvals rose each quarter, from 53 in the first quarter to 61 in the second and 89 in the third.
Of the 89 third-quarter trials, 78 were multinational studies.
In third-quarter approvals, phase 3 trials accounted for 45, or 50.6 percent.
Antibody-related medicines made up 74.2 percent of third-quarter approvals, and oncology was the leading treatment area.
- Who
- South Korea approved the trials.
- What
- It approved 203 biopharmaceutical clinical trials from January through September 2026.
- When
- January through September 2026.
- Where
- South Korea.
- Why
- Not stated
This story does not have two clearly opposing sides.
South Korea approved 53 biopharmaceutical clinical trials.
South Korea approved 61 biopharmaceutical clinical trials.
South Korea approved 89 biopharmaceutical clinical trials.
- Total approvals
- 203 trials from January through September 2026
- First-quarter approvals
- 53
- Second-quarter approvals
- 61
- Third-quarter approvals
- 89
- Multinational third-quarter trials
- 78 of 89, or 87.6 percent
- Phase 3 third-quarter trials
- 45, or 50.6 percent
1 source
What people are saying
Participation in early-phase trials continued, alongside large-scale late-phase trials.